BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 9135875)

  • 1. Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates.
    Kessler JA; McKenna PM; Emini EA; Chan CP; Patel MD; Gupta SK; Mark GE; Barbas CF; Burton DR; Conley AJ
    AIDS Res Hum Retroviruses; 1997 May; 13(7):575-82. PubMed ID: 9135875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.
    Zhang MY; Xiao X; Sidorov IA; Choudhry V; Cham F; Zhang PF; Bouma P; Zwick M; Choudhary A; Montefiori DC; Broder CC; Burton DR; Quinnan GV; Dimitrov DS
    J Virol; 2004 Sep; 78(17):9233-42. PubMed ID: 15308718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
    Roben P; Moore JP; Thali M; Sodroski J; Barbas CF; Burton DR
    J Virol; 1994 Aug; 68(8):4821-8. PubMed ID: 7518527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.
    Trkola A; Pomales AB; Yuan H; Korber B; Maddon PJ; Allaway GP; Katinger H; Barbas CF; Burton DR; Ho DD
    J Virol; 1995 Nov; 69(11):6609-17. PubMed ID: 7474069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.
    Moore JP; Cao Y; Qing L; Sattentau QJ; Pyati J; Koduri R; Robinson J; Barbas CF; Burton DR; Ho DD
    J Virol; 1995 Jan; 69(1):101-9. PubMed ID: 7527081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polyclonal immunoglobulin G from patients neutralizes human immunodeficiency virus type 1 primary isolates by binding free virions, but without interfering with an initial CD4-independent attachment of the virus to primary blood mononuclear cells.
    Burrer R; Haessig-Einius S; Aubertin AM; Moog C
    J Virol; 2003 Nov; 77(21):11385-97. PubMed ID: 14557624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off.
    Mo H; Stamatatos L; Ip JE; Barbas CF; Parren PW; Burton DR; Moore JP; Ho DD
    J Virol; 1997 Sep; 71(9):6869-74. PubMed ID: 9261412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a postfusion event.
    McInerney TL; McLain L; Armstrong SJ; Dimmock NJ
    Virology; 1997 Jul; 233(2):313-26. PubMed ID: 9217055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a novel CD4i human monoclonal antibody Fab that neutralizes HIV-1 primary isolates from different clades.
    Zhang MY; Shu Y; Sidorov I; Dimitrov DS
    Antiviral Res; 2004 Mar; 61(3):161-4. PubMed ID: 15168796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro.
    Barbas CF; Björling E; Chiodi F; Dunlop N; Cababa D; Jones TM; Zebedee SL; Persson MA; Nara PL; Norrby E
    Proc Natl Acad Sci U S A; 1992 Oct; 89(19):9339-43. PubMed ID: 1384050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.
    Burton DR; Pyati J; Koduri R; Sharp SJ; Thornton GB; Parren PW; Sawyer LS; Hendry RM; Dunlop N; Nara PL
    Science; 1994 Nov; 266(5187):1024-7. PubMed ID: 7973652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric viruses expressing primary envelope glycoproteins of human immunodeficiency virus type I show increased sensitivity to neutralization by human sera.
    McKeating JA; Zhang YJ; Arnold C; Frederiksson R; Fenyö EM; Balfe P
    Virology; 1996 Jun; 220(2):450-60. PubMed ID: 8661395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a mouse/human chimeric monoclonal antibody (C beta 1) to a principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.
    Matsushita S; Maeda H; Kimachi K; Eda Y; Maeda Y; Murakami T; Tokiyoshi S; Takatsuki K
    AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1107-15. PubMed ID: 1380258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
    Klasse PJ; McKeating JA; Schutten M; Reitz MS; Robert-Guroff M
    Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.
    Pugach P; Kuhmann SE; Taylor J; Marozsan AJ; Snyder A; Ketas T; Wolinsky SM; Korber BT; Moore JP
    Virology; 2004 Mar; 321(1):8-22. PubMed ID: 15033560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Herpesvirus saimiri-immortalized human lymphocytes: novel hosts for analyzing HIV type 1 in vitro neutralization.
    Vella C; Zheng NN; Easterbrook P; Daniels RS
    AIDS Res Hum Retroviruses; 2002 Sep; 18(13):933-46. PubMed ID: 12230936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 neutralization by chimeric CD4-CG10 polypeptides fused to human IgG1.
    Meyuhas R; Noy H; Montefiori DC; Denisova G; Gershoni JM; Gross G
    Mol Immunol; 2005 May; 42(9):1099-109. PubMed ID: 15829299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of soluble CD4-mediated HIV neutralization and gp 120 binding by CD4 autoantibodies and monoclonal antibodies.
    Moore JP; Sattentau QJ; Clapham PR
    AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1273-9. PubMed ID: 2078408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.